Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0046 | 0.2261 | 0.7094 |
Plasmodium vivax | glutathione reductase, putative | 0.0046 | 0.2261 | 1 |
Schistosoma mansoni | zinc finger protein | 0.0019 | 0.0189 | 0.0189 |
Plasmodium falciparum | thioredoxin reductase | 0.0046 | 0.2261 | 1 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0046 | 0.2261 | 0.7094 |
Loa Loa (eye worm) | hypothetical protein | 0.0038 | 0.1593 | 0.3972 |
Brugia malayi | Thioredoxin reductase | 0.0046 | 0.2261 | 0.4471 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0022 | 0.041 | 0.1287 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0106 | 0.679 | 0.8342 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0118 | 0.769 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0059 | 0.3187 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.061 | 0.1521 |
Leishmania major | trypanothione reductase | 0.0046 | 0.2261 | 1 |
Toxoplasma gondii | thioredoxin reductase | 0.0046 | 0.2261 | 1 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.0118 | 0.769 | 1 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0046 | 0.2261 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0069 | 0.4011 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.0118 | 0.769 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0046 | 0.2261 | 0.5637 |
Brugia malayi | Bromodomain containing protein | 0.0074 | 0.433 | 1 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0022 | 0.041 | 0.1287 |
Mycobacterium tuberculosis | Probable reductase | 0.0106 | 0.679 | 0.8342 |
Brugia malayi | Bromodomain containing protein | 0.0038 | 0.1588 | 0.2673 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0046 | 0.2261 | 1 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0106 | 0.679 | 0.8342 |
Schistosoma mansoni | hypothetical protein | 0.002 | 0.0268 | 0.0268 |
Echinococcus granulosus | zinc finger protein | 0.0019 | 0.0189 | 0.0592 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0035 | 0.1411 | 0.4427 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0017 | 0.0046 | 0.0114 |
Schistosoma mansoni | bromodomain containing protein | 0.0062 | 0.3455 | 0.3455 |
Brugia malayi | glutathione reductase | 0.0046 | 0.2261 | 0.4471 |
Echinococcus multilocularis | zinc finger protein | 0.0019 | 0.0189 | 0.0592 |
Loa Loa (eye worm) | PHD-finger family protein | 0.002 | 0.0268 | 0.0667 |
Trypanosoma brucei | trypanothione reductase | 0.0046 | 0.2261 | 1 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0106 | 0.679 | 0.8342 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0035 | 0.1411 | 0.4427 |
Brugia malayi | hypothetical protein | 0.0025 | 0.061 | 0.0061 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.0118 | 0.769 | 1 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0106 | 0.679 | 0.8342 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0022 | 0.041 | 0.041 |
Loa Loa (eye worm) | hypothetical protein | 0.0042 | 0.1913 | 0.4769 |
Plasmodium falciparum | glutathione reductase | 0.0046 | 0.2261 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0046 | 0.2261 | 0.5637 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0059 | 0.3187 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.177 | 0.4413 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0106 | 0.679 | 0.8342 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.